Teon Therapeutics is a global biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy. Headquartered in the San Francisco Bay Area and backed by Venture Capitals, Teon is committed to advance innovative therapeutic agents to address unmet global medical needs and improve the lives of patients.
To improve long-term outcomes for more patients with cancer, we believe more Immuno-Oncology based combinations may be required.
With this core philosophy in mind, our first-in-class small molecule checkpoint inhibitors (A2B & UDT-1) are the backbone of our IO portfolio and offer differentiated combination therapies with our other potentially best in-class checkpoint inhibitors.
Our executive team has extensive pharmaceutical industry experience and a proven track record of successful drug discovery, development and launching in multiple therapeutic areas.